Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) issued a Form 8-K on November 10, 2026, announcing financial results for the third quarter of 2026 and providing an update on its clinical pipeline. The company reported a cash position of $430.2 million as of September 30, 2026, down from $457.5 million at the end of the previous quarter. Hemab stated that this cash balance is expected to fund its operating expenses and capital expenditure requirements through 2029.
For the three months ended September 30, 2026, the company reported research and development expenses of $24.6 million, a significant increase from $14.6 million in the same period in 2025. General and administrative expenses rose to $5.1 million from $2.5 million year-over-year. The company recorded a net loss of $27.3 million, or $0.58 per share, for the quarter.
In terms of clinical development, Hemab announced the initiation of SOLARA, an open-label, single-arm, multicenter Phase 3 trial for sutacimig in Glanzmann thrombasthenia (GT). The trial is enrolling approximately 75 participants aged 12 to 70 years who have experienced at least four treated bleeding events in the prior 12 months. The SOLARA trial consists of a 24-week run-in period followed by a 48-week treatment period where participants receive sutacimig 0.2 mg/kg via subcutaneous injection once weekly. The primary endpoint is the annualized treated bleed rate (ATBR) during the treatment period compared to the run-in period.
Separately, Hemab reported first clinical data from its Phase 2b trial of sutacimig in Factor VII deficiency (FVIID). Two participants with severe congenital FVIID received a single subcutaneous dose, resulting in a shortening of prothrombin time by more than 50% in both individuals. In the participant with available pharmacokinetics and pharmacodynamics data, sutacimig produced an accumulation of endogenous Factor VIIa approximately 5 times higher than baseline, with exposure maintained through Day 22.
The company also provided updates on its HMB-002 program for Von Willebrand Disease and its HMB-003 program for heavy menstrual bleeding. Hemab dosed the first participant in the Phase 1 trial of HMB-003 in September 2026. Preclinical data presented at the 68th ASH Annual Meeting and Exposition in December 2026 showed that HMB-003 reduced severe bleeding days in a cynomolgus monkey model. The company expects to present additional data from the VELORA Pioneer Phase 1/2 trial of HMB-002 at the 20th EAHAD Congress in February 2027.
On the corporate side, Hemab announced the appointment of Keli Walbert to its Board of Directors in September 2026. Ms. Walbert brings over 20 years of commercial leadership experience in the biopharmaceutical industry.
